Crowley Wealth Management Inc. Invests $503,000 in Johnson & Johnson (NYSE:JNJ)

Crowley Wealth Management Inc. purchased a new stake in shares of Johnson & Johnson (NYSE:JNJ - Free Report) during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm purchased 3,478 shares of the company's stock, valued at approximately $503,000.

Several other institutional investors and hedge funds have also recently made changes to their positions in the company. Vinva Investment Management Ltd raised its stake in Johnson & Johnson by 6.8% in the third quarter. Vinva Investment Management Ltd now owns 111,448 shares of the company's stock valued at $17,988,000 after buying an additional 7,110 shares during the last quarter. Financial Counselors Inc. raised its position in shares of Johnson & Johnson by 5.3% in the 3rd quarter. Financial Counselors Inc. now owns 185,093 shares of the company's stock valued at $29,996,000 after purchasing an additional 9,309 shares during the last quarter. Oregon Pacific Wealth Management LLC acquired a new stake in Johnson & Johnson in the 4th quarter worth approximately $949,000. Horan Securities Inc. grew its position in Johnson & Johnson by 1.3% during the 4th quarter. Horan Securities Inc. now owns 7,178 shares of the company's stock worth $1,038,000 after purchasing an additional 90 shares during the last quarter. Finally, Strategic Financial Concepts LLC increased its stake in Johnson & Johnson by 57.9% during the 4th quarter. Strategic Financial Concepts LLC now owns 3,467 shares of the company's stock valued at $501,000 after purchasing an additional 1,271 shares in the last quarter. 69.55% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

A number of equities research analysts have recently weighed in on the stock. Raymond James dropped their price objective on shares of Johnson & Johnson from $170.00 to $165.00 and set an "outperform" rating on the stock in a report on Thursday, January 23rd. Barclays increased their price objective on Johnson & Johnson from $159.00 to $166.00 and gave the company an "equal weight" rating in a report on Tuesday, January 28th. Citigroup decreased their target price on Johnson & Johnson from $185.00 to $175.00 and set a "buy" rating for the company in a report on Wednesday, December 11th. Stifel Nicolaus cut their price target on shares of Johnson & Johnson from $170.00 to $155.00 and set a "hold" rating on the stock in a report on Thursday, January 23rd. Finally, Royal Bank of Canada restated an "outperform" rating and set a $181.00 price objective on shares of Johnson & Johnson in a research note on Wednesday, February 19th. Nine investment analysts have rated the stock with a hold rating, eight have issued a buy rating and two have given a strong buy rating to the stock. According to MarketBeat, Johnson & Johnson has an average rating of "Moderate Buy" and an average price target of $171.33.

Remove Ads

Insider Activity at Johnson & Johnson

In other Johnson & Johnson news, VP Robert J. Decker sold 6,999 shares of the firm's stock in a transaction on Tuesday, February 25th. The stock was sold at an average price of $165.88, for a total value of $1,160,994.12. Following the transaction, the vice president now owns 21,001 shares in the company, valued at approximately $3,483,645.88. This trade represents a 25.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, EVP Timothy Schmid sold 403 shares of the company's stock in a transaction on Tuesday, February 18th. The stock was sold at an average price of $156.15, for a total transaction of $62,928.45. Following the sale, the executive vice president now directly owns 15,098 shares of the company's stock, valued at $2,357,552.70. The trade was a 2.60 % decrease in their position. The disclosure for this sale can be found here. 0.16% of the stock is currently owned by corporate insiders.

Johnson & Johnson Price Performance

JNJ stock traded down $1.65 during mid-day trading on Tuesday, reaching $161.64. 2,234,239 shares of the company's stock were exchanged, compared to its average volume of 7,088,162. The company has a debt-to-equity ratio of 0.43, a current ratio of 1.11 and a quick ratio of 0.86. Johnson & Johnson has a 12-month low of $140.68 and a 12-month high of $169.99. The stock's 50 day moving average is $157.37 and its 200 day moving average is $156.16. The company has a market cap of $389.53 billion, a price-to-earnings ratio of 24.30, a price-to-earnings-growth ratio of 2.56 and a beta of 0.47.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last released its quarterly earnings results on Wednesday, January 22nd. The company reported $2.04 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.99 by $0.05. The firm had revenue of $22.52 billion for the quarter, compared to analysts' expectations of $22.44 billion. Johnson & Johnson had a net margin of 18.20% and a return on equity of 34.24%. The firm's revenue for the quarter was up 5.3% compared to the same quarter last year. During the same quarter last year, the company earned $2.29 EPS. On average, research analysts expect that Johnson & Johnson will post 10.58 EPS for the current year.

Johnson & Johnson Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Tuesday, March 4th. Investors of record on Tuesday, February 18th were given a dividend of $1.24 per share. The ex-dividend date of this dividend was Tuesday, February 18th. This represents a $4.96 annualized dividend and a dividend yield of 3.07%. Johnson & Johnson's dividend payout ratio (DPR) is presently 74.59%.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.